Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada
Open Access
- 9 July 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74 (7), 1158-1165
- https://doi.org/10.1093/cid/ciab616
Abstract
Randomized-controlled trials of mRNA vaccine protection against SARS-CoV-2 included few elderly participants. We assess single-dose mRNA vaccine effectiveness (VE) in adults ≥70-years-old in British Columbia (BC), Canada where second doses were deferred by up to 16 weeks and where a spring 2021 wave uniquely included co-dominant circulation of Alpha (B.1.1.7) and Gamma (P.1) variants of concern (VOC). Analyses included community-dwelling adults ≥70-years-old with specimen collection between April 4 (epidemiological week 14) and May 1 (week 17) 2021. Adjusted VE was estimated by test-negative design. Cases were RT-PCR test-positive for SARS-CoV-2 and controls were test-negative. Vaccine status was defined by receipt of a single-dose ≥21 days before specimen collection, but a range of intervals was assessed. Variant-specific VE was estimated against viruses genetically characterized as Alpha, Gamma or non-VOC lineages. VE analyses included 16,993 specimens: 1,226 (7.2%) test-positive cases and 15,767 test-negative controls. Of 1,131 (92%) genetically-characterized viruses, 509 (45%), 314 (28%) and 276 (24%) were Alpha, Gamma and non-VOC lineages, respectively. At 0-13 days post-vaccination, VE was negligible at 14% (95% CI 0-26) but increased from 43% (95% CI 30-53) at 14-20 days to 75% (95% CI 63-83) at 35-41 days post-vaccination. VE at ≥21 days post-vaccination was 65% (95% CI 58-71) overall: 72% (95% CI 58-81), 67% (95% CI 57-75) and 61% (95% CI 45-72) for non-VOC, Alpha and Gamma variants, respectively. A single dose of mRNA vaccine reduced the risk of SARS-CoV-2 by about two-thirds in adults ≥70-years-old, with protection only minimally reduced against Alpha and Gamma variants.Funding Information
- BC Children’s Hospital Foundation
- Canadian Child Health Clinician Scientist Program,
- Michael Smith Foundation for Health Research
- Public Health Agency of Canada
- Canadian Institutes of Health Research
- Roche, Hologic, and Siemens
- GlaxoSmithKline
- Merck
- Pfizer
- Sanofi-Pasteur
- Seqirus
- Symvivo
This publication has 11 references indexed in Scilit:
- Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design studyBMJ, 2021
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) VariantThe New England Journal of Medicine, 2021
- Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic SeraJournal of Virology, 2021
- Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control studyBMJ, 2021
- Antibody evasion by the P.1 strain of SARS-CoV-2Cell, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Sex-based Biology and the Rational Design of Influenza Vaccination StrategiesThe Journal of Infectious Diseases, 2014
- The Gracefully Aging Immune SystemScience Translational Medicine, 2013